Massachusetts-based biotechnology company HotSpot Therapeutics has raised USD 100 million in an oversubscribed Series C funding round led by Pivotal BioVenture Partners. New investors, including Revelation Partners and Pavilion Capital, as well as existing investors Atlas Venture and Sofinnova Partners, also participated in the round.
The funds will be directed toward further developing the company’s platform Smart Allostery, which entails a broad range of AI-enabled technologies, along with a hotspot-specific chemical library. The company also intends to use the funds to advance its pipeline and plans to begin clinical trials for one of its lung cancer-related products next year.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.